menu
    • menu

    Company profile for Cantargia AB

    NEW Drugs in Dev: 4
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap). Cantargia AB was formed in 2009-201...
    Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap). Cantargia AB was formed in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cantargia ABSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Medicon Village, Scheelevägen 2 SE-223 81 Lund
    Telephone
    Telephone
    +46(0)46 2756260
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cantargia.com/en/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cantargia-ab
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/cantargia?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cantargia to Host Webcast on Rights Issue and Strategy Priorities
    Cantargia to Host Webcast on Rights Issue and Strategy Priorities

    28 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-28/cantargia-ab-to-host-webcast-covering-rights-issue-loan-agreement-and-strategic-priorities

    PHARMIWEB
    28 May 2026
    Share Share
    Cantargia AB: Annual General Meeting Bulletin
    Cantargia AB: Annual General Meeting Bulletin

    21 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-21/bulletin-from-the-annual-general-meeting-in-cantargia-ab-publ

    PHARMIWEB
    21 May 2026
    Share Share
    Cantargia Publishes Interim Report For The First Quarter Of 2026
    Cantargia Publishes Interim Report For The First Quarter Of 2026

    19 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-19/cantargia-publishes-interim-report-for-the-first-quarter-of-2026

    PHARMIWEB
    19 May 2026
    Share Share
    Cantargia To Present Q1 2026 Interim Report
    Cantargia To Present Q1 2026 Interim Report

    06 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-06/invitation-to-the-presentation-of-cantargias-interim-report-for-q1-2026

    PHARMIWEB
    06 May 2026
    Share Share
    Cantargia Reports Early Nadunolimab Trial Results In MDS And AML
    Cantargia Reports Early Nadunolimab Trial Results In MDS And AML

    27 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-27/cantargia-announces-early-results-from-trial-of-nadunolimab-in-mds-and-aml

    PHARMIWEB
    27 Apr 2026
    Share Share
    Cantargia Unveils AACR 2026 Presentation On Nadunolimab Study
    Cantargia Unveils AACR 2026 Presentation On Nadunolimab Study

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187529

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search